 Michael Mitchell
Concepts (784)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 107 | 2026 | 517 | 37.600 |
Why?
| | Lipids | 65 | 2026 | 707 | 23.060 |
Why?
| | RNA, Messenger | 58 | 2026 | 2805 | 16.620 |
Why?
| | Liposomes | 79 | 2026 | 263 | 12.760 |
Why?
| | Drug Delivery Systems | 27 | 2026 | 381 | 7.950 |
Why?
| | Gene Editing | 15 | 2026 | 89 | 6.250 |
Why?
| | Immunotherapy | 17 | 2026 | 667 | 5.080 |
Why?
| | T-Lymphocytes | 18 | 2026 | 1997 | 4.860 |
Why?
| | Mice | 114 | 2026 | 18355 | 3.970 |
Why?
| | Gene Transfer Techniques | 11 | 2026 | 187 | 3.950 |
Why?
| | Neoplasms | 22 | 2026 | 2913 | 3.830 |
Why?
| | Animals | 152 | 2026 | 38097 | 3.610 |
Why?
| | Placenta | 9 | 2026 | 787 | 3.540 |
Why?
| | Infertility, Male | 12 | 2026 | 80 | 3.290 |
Why?
| | RNA, Small Interfering | 22 | 2026 | 638 | 3.120 |
Why?
| | Y Chromosome | 29 | 2016 | 37 | 3.010 |
Why?
| | CRISPR-Cas Systems | 6 | 2025 | 166 | 2.810 |
Why?
| | Neoplastic Cells, Circulating | 9 | 2015 | 81 | 2.720 |
Why?
| | High-Throughput Screening Assays | 4 | 2026 | 177 | 2.570 |
Why?
| | Cancer Vaccines | 6 | 2026 | 162 | 2.530 |
Why?
| | Autoimmune Diseases | 4 | 2025 | 469 | 2.490 |
Why?
| | Spermatogenesis | 20 | 2026 | 91 | 2.470 |
Why?
| | Cell Engineering | 6 | 2026 | 15 | 2.400 |
Why?
| | Immunotherapy, Adoptive | 6 | 2026 | 342 | 2.360 |
Why?
| | Spermatozoa | 9 | 2026 | 107 | 2.260 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 6 | 2024 | 54 | 2.000 |
Why?
| | Transfection | 12 | 2026 | 927 | 1.950 |
Why?
| | Humans | 176 | 2026 | 145763 | 1.930 |
Why?
| | Nanomedicine | 7 | 2026 | 47 | 1.910 |
Why?
| | Cell Line, Tumor | 22 | 2026 | 3551 | 1.880 |
Why?
| | Chromosomes, Human, Y | 10 | 2012 | 37 | 1.740 |
Why?
| | Endosomes | 3 | 2025 | 140 | 1.720 |
Why?
| | Ribonucleoproteins | 2 | 2025 | 89 | 1.660 |
Why?
| | Antibodies, Bispecific | 2 | 2025 | 68 | 1.610 |
Why?
| | Antineoplastic Agents | 6 | 2026 | 2219 | 1.590 |
Why?
| | Nanostructures | 5 | 2024 | 105 | 1.590 |
Why?
| | Nucleic Acids | 2 | 2025 | 70 | 1.580 |
Why?
| | Mice, Inbred C57BL | 24 | 2026 | 5992 | 1.530 |
Why?
| | DNA-Binding Proteins | 11 | 2026 | 1482 | 1.470 |
Why?
| | Leukocytes | 7 | 2023 | 296 | 1.440 |
Why?
| | Liver | 7 | 2026 | 1899 | 1.420 |
Why?
| | Microfluidics | 5 | 2025 | 61 | 1.400 |
Why?
| | Genetic Therapy | 6 | 2024 | 316 | 1.350 |
Why?
| | Blood-Brain Barrier | 5 | 2026 | 160 | 1.340 |
Why?
| | Drug Carriers | 6 | 2026 | 136 | 1.300 |
Why?
| | Spleen | 2 | 2025 | 508 | 1.300 |
Why?
| | Nuclear Proteins | 11 | 2026 | 740 | 1.300 |
Why?
| | Tumor Microenvironment | 10 | 2026 | 735 | 1.290 |
Why?
| | Peptides | 4 | 2025 | 998 | 1.280 |
Why?
| | Vaccines | 3 | 2026 | 389 | 1.270 |
Why?
| | Oligospermia | 5 | 2016 | 13 | 1.260 |
Why?
| | RNA | 4 | 2026 | 912 | 1.210 |
Why?
| | Cyclodextrins | 2 | 2020 | 11 | 1.200 |
Why?
| | Biomedical Engineering | 2 | 2020 | 30 | 1.180 |
Why?
| | Spermatids | 4 | 2026 | 25 | 1.160 |
Why?
| | Brain | 6 | 2026 | 2969 | 1.160 |
Why?
| | Azoospermia | 5 | 2017 | 10 | 1.130 |
Why?
| | Nuclear Pore Complex Proteins | 2 | 2026 | 40 | 1.120 |
Why?
| | Lab-On-A-Chip Devices | 4 | 2025 | 61 | 1.110 |
Why?
| | Stress, Mechanical | 7 | 2017 | 494 | 1.060 |
Why?
| | Dendrimers | 2 | 2025 | 21 | 1.040 |
Why?
| | Transcription Factors | 11 | 2016 | 1736 | 1.030 |
Why?
| | Antigen-Presenting Cells | 2 | 2026 | 159 | 1.020 |
Why?
| | DNA | 9 | 2024 | 1437 | 1.010 |
Why?
| | Diphosphonates | 2 | 2024 | 68 | 1.010 |
Why?
| | Sperm Head | 2 | 2017 | 5 | 1.000 |
Why?
| | Surface-Active Agents | 3 | 2021 | 98 | 0.990 |
Why?
| | E-Selectin | 4 | 2015 | 61 | 0.980 |
Why?
| | Colonic Neoplasms | 2 | 2026 | 258 | 0.970 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2026 | 35 | 0.960 |
Why?
| | Mouth Neoplasms | 1 | 2026 | 90 | 0.910 |
Why?
| | Prodrugs | 1 | 2026 | 52 | 0.910 |
Why?
| | Extracellular Vesicles | 2 | 2026 | 171 | 0.900 |
Why?
| | Exosomes | 2 | 2023 | 104 | 0.890 |
Why?
| | Nanotubes | 3 | 2015 | 46 | 0.880 |
Why?
| | Lymph Nodes | 2 | 2026 | 509 | 0.880 |
Why?
| | Membrane Proteins | 5 | 2026 | 1166 | 0.870 |
Why?
| | Biocompatible Materials | 3 | 2019 | 429 | 0.860 |
Why?
| | Bone Marrow | 2 | 2023 | 307 | 0.860 |
Why?
| | Siloxanes | 1 | 2024 | 7 | 0.860 |
Why?
| | HIV | 1 | 2026 | 251 | 0.850 |
Why?
| | Amidines | 1 | 2024 | 13 | 0.850 |
Why?
| | Female | 67 | 2026 | 79035 | 0.840 |
Why?
| | Endothelial Cells | 9 | 2024 | 877 | 0.840 |
Why?
| | Pyridones | 1 | 2026 | 209 | 0.840 |
Why?
| | Cations | 1 | 2024 | 83 | 0.830 |
Why?
| | Amantadine | 1 | 2024 | 8 | 0.830 |
Why?
| | Apoptosis | 9 | 2024 | 2443 | 0.820 |
Why?
| | Skin Diseases | 1 | 2026 | 152 | 0.820 |
Why?
| | Oncolytic Viruses | 1 | 2024 | 8 | 0.820 |
Why?
| | Oncolytic Virotherapy | 1 | 2024 | 13 | 0.810 |
Why?
| | Genital Neoplasms, Female | 1 | 2025 | 99 | 0.810 |
Why?
| | Microtubules | 1 | 2026 | 265 | 0.790 |
Why?
| | CD3 Complex | 1 | 2024 | 112 | 0.790 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2024 | 552 | 0.790 |
Why?
| | Polymers | 5 | 2026 | 485 | 0.790 |
Why?
| | Antigens, Neoplasm | 3 | 2026 | 271 | 0.780 |
Why?
| | Pregnancy | 11 | 2026 | 7215 | 0.780 |
Why?
| | X Chromosome | 13 | 2016 | 66 | 0.780 |
Why?
| | Placenta Diseases | 1 | 2023 | 20 | 0.780 |
Why?
| | Cystic Fibrosis | 2 | 2025 | 1163 | 0.770 |
Why?
| | Neurotoxicity Syndromes | 1 | 2023 | 40 | 0.770 |
Why?
| | Neutrophil Activation | 2 | 2014 | 84 | 0.750 |
Why?
| | Hypersensitivity | 1 | 2025 | 254 | 0.750 |
Why?
| | Wnt Proteins | 2 | 2026 | 133 | 0.740 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2023 | 80 | 0.740 |
Why?
| | Bile Acids and Salts | 1 | 2024 | 163 | 0.730 |
Why?
| | Killer Cells, Natural | 3 | 2025 | 481 | 0.730 |
Why?
| | Spermatocytes | 7 | 2014 | 18 | 0.730 |
Why?
| | Lung | 7 | 2025 | 4116 | 0.730 |
Why?
| | Pre-Eclampsia | 1 | 2024 | 206 | 0.720 |
Why?
| | Mesothelioma | 1 | 2022 | 52 | 0.720 |
Why?
| | Dendritic Cells | 5 | 2026 | 500 | 0.720 |
Why?
| | Bone and Bones | 1 | 2024 | 318 | 0.710 |
Why?
| | Trophoblasts | 4 | 2025 | 218 | 0.700 |
Why?
| | Precision Medicine | 3 | 2020 | 461 | 0.690 |
Why?
| | Antioxidants | 1 | 2025 | 550 | 0.690 |
Why?
| | Wnt Signaling Pathway | 2 | 2026 | 212 | 0.680 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2025 | 373 | 0.680 |
Why?
| | Polyethylene Glycols | 5 | 2026 | 649 | 0.680 |
Why?
| | Placental Insufficiency | 1 | 2023 | 126 | 0.680 |
Why?
| | Protein Corona | 3 | 2026 | 9 | 0.680 |
Why?
| | Amniotic Fluid | 1 | 2021 | 79 | 0.670 |
Why?
| | Shear Strength | 4 | 2015 | 73 | 0.670 |
Why?
| | Fatty Acids | 1 | 2024 | 457 | 0.670 |
Why?
| | Testis | 6 | 2023 | 162 | 0.670 |
Why?
| | Meiosis | 10 | 2015 | 101 | 0.660 |
Why?
| | Skin | 1 | 2026 | 754 | 0.650 |
Why?
| | ErbB Receptors | 1 | 2024 | 635 | 0.650 |
Why?
| | Chromosome Mapping | 16 | 2001 | 507 | 0.650 |
Why?
| | Polyneuropathies | 1 | 2021 | 57 | 0.650 |
Why?
| | Sperm Tail | 3 | 2018 | 8 | 0.650 |
Why?
| | Exons | 6 | 2017 | 364 | 0.640 |
Why?
| | Flow Cytometry | 1 | 2024 | 1165 | 0.640 |
Why?
| | Microfluidic Analytical Techniques | 3 | 2025 | 79 | 0.630 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 411 | 0.630 |
Why?
| | Biomimetic Materials | 2 | 2026 | 78 | 0.630 |
Why?
| | Fetal Therapies | 1 | 2020 | 47 | 0.620 |
Why?
| | Mutation | 6 | 2018 | 4090 | 0.620 |
Why?
| | Gene Deletion | 7 | 2017 | 392 | 0.610 |
Why?
| | Structure-Activity Relationship | 3 | 2026 | 563 | 0.600 |
Why?
| | Cell Proliferation | 3 | 2026 | 2514 | 0.600 |
Why?
| | Multiple Myeloma | 1 | 2023 | 309 | 0.600 |
Why?
| | Sperm Motility | 2 | 2018 | 37 | 0.580 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 171 | 0.570 |
Why?
| | Calmodulin-Binding Proteins | 1 | 2018 | 13 | 0.560 |
Why?
| | Fetal Diseases | 1 | 2020 | 194 | 0.560 |
Why?
| | Histones | 2 | 2023 | 666 | 0.560 |
Why?
| | Factor IX | 3 | 2015 | 49 | 0.550 |
Why?
| | Calmodulin | 1 | 2018 | 70 | 0.550 |
Why?
| | Proteins | 7 | 2023 | 1023 | 0.540 |
Why?
| | Neoplasm Metastasis | 4 | 2015 | 688 | 0.540 |
Why?
| | Natural Science Disciplines | 1 | 2017 | 2 | 0.530 |
Why?
| | Hemophilia B | 3 | 2015 | 65 | 0.530 |
Why?
| | Pyrazines | 1 | 2018 | 94 | 0.530 |
Why?
| | Cholesterol | 3 | 2025 | 408 | 0.520 |
Why?
| | Tissue Distribution | 5 | 2026 | 335 | 0.510 |
Why?
| | Sequence Deletion | 7 | 2017 | 191 | 0.480 |
Why?
| | Lamin Type A | 2 | 2015 | 49 | 0.480 |
Why?
| | Hydrogels | 1 | 2023 | 701 | 0.470 |
Why?
| | Aluminum Silicates | 2 | 2015 | 17 | 0.470 |
Why?
| | Base Sequence | 18 | 2012 | 2171 | 0.460 |
Why?
| | Male | 64 | 2026 | 73003 | 0.450 |
Why?
| | Selectins | 1 | 2015 | 8 | 0.450 |
Why?
| | Gene Duplication | 1 | 2015 | 66 | 0.450 |
Why?
| | Antibodies, Neoplasm | 1 | 2015 | 34 | 0.440 |
Why?
| | Lipoproteins | 2 | 2026 | 166 | 0.440 |
Why?
| | Molecular Sequence Data | 21 | 2012 | 2883 | 0.430 |
Why?
| | Coated Materials, Biocompatible | 1 | 2015 | 65 | 0.430 |
Why?
| | Pyridines | 2 | 2018 | 609 | 0.420 |
Why?
| | Medical Oncology | 1 | 2017 | 340 | 0.420 |
Why?
| | Mutation, Missense | 4 | 2017 | 335 | 0.420 |
Why?
| | Platelet Activating Factor | 1 | 2014 | 45 | 0.420 |
Why?
| | Ligases | 4 | 2000 | 38 | 0.410 |
Why?
| | Excipients | 2 | 2024 | 55 | 0.410 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 181 | 0.410 |
Why?
| | Chemical Phenomena | 1 | 2013 | 77 | 0.400 |
Why?
| | Kruppel-Like Transcription Factors | 3 | 2014 | 83 | 0.400 |
Why?
| | Autoimmunity | 3 | 2024 | 933 | 0.400 |
Why?
| | Glycocalyx | 1 | 2013 | 30 | 0.390 |
Why?
| | Cell Adhesion | 4 | 2015 | 451 | 0.380 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2025 | 78 | 0.380 |
Why?
| | Adjuvants, Immunologic | 2 | 2025 | 244 | 0.370 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 605 | 0.370 |
Why?
| | Health Services Accessibility | 1 | 2021 | 1101 | 0.370 |
Why?
| | Phospholipids | 2 | 2025 | 214 | 0.370 |
Why?
| | Factor V | 2 | 2019 | 26 | 0.360 |
Why?
| | Hematopoietic Stem Cells | 3 | 2024 | 435 | 0.360 |
Why?
| | Receptors, Formyl Peptide | 1 | 2012 | 17 | 0.360 |
Why?
| | Inverted Repeat Sequences | 1 | 2011 | 18 | 0.350 |
Why?
| | Mitochondria | 1 | 2018 | 992 | 0.340 |
Why?
| | Neutrophils | 4 | 2023 | 1125 | 0.330 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2012 | 140 | 0.330 |
Why?
| | Factor V Deficiency | 1 | 2010 | 2 | 0.330 |
Why?
| | Transcriptional Activation | 2 | 2014 | 372 | 0.330 |
Why?
| | Factor VIII | 3 | 2007 | 106 | 0.330 |
Why?
| | RNA-Binding Proteins | 4 | 2005 | 447 | 0.330 |
Why?
| | Mice, Nude | 2 | 2024 | 680 | 0.310 |
Why?
| | Point Mutation | 2 | 2008 | 241 | 0.300 |
Why?
| | Ligands | 3 | 2024 | 668 | 0.300 |
Why?
| | Amino Acid Substitution | 2 | 2008 | 302 | 0.300 |
Why?
| | Emigration and Immigration | 1 | 2010 | 66 | 0.300 |
Why?
| | Doxorubicin | 1 | 2012 | 403 | 0.300 |
Why?
| | Mice, Knockout | 5 | 2026 | 3130 | 0.300 |
Why?
| | L-Selectin | 3 | 2014 | 27 | 0.300 |
Why?
| | Chromosome Deletion | 3 | 2011 | 126 | 0.290 |
Why?
| | Pseudogenes | 2 | 2000 | 20 | 0.290 |
Why?
| | DNA, Mitochondrial | 1 | 2010 | 211 | 0.290 |
Why?
| | Immunity, Innate | 3 | 2026 | 835 | 0.290 |
Why?
| | Hemodynamics | 1 | 2014 | 1118 | 0.290 |
Why?
| | Transcription, Genetic | 4 | 2012 | 1454 | 0.280 |
Why?
| | Protamines | 1 | 2008 | 8 | 0.280 |
Why?
| | Nuclear Lamina | 3 | 2017 | 12 | 0.270 |
Why?
| | Cardiac Tamponade | 1 | 2007 | 15 | 0.270 |
Why?
| | Hemophilia A | 3 | 2007 | 148 | 0.260 |
Why?
| | Social Class | 1 | 2009 | 264 | 0.260 |
Why?
| | Factor XI Deficiency | 1 | 2007 | 3 | 0.260 |
Why?
| | Factor XI | 1 | 2007 | 11 | 0.260 |
Why?
| | Chromosomes, Human, X | 2 | 2007 | 77 | 0.260 |
Why?
| | Genetic Variation | 2 | 2010 | 976 | 0.260 |
Why?
| | Biopsy, Needle | 1 | 2007 | 185 | 0.250 |
Why?
| | Prescription Drugs | 2 | 2020 | 111 | 0.250 |
Why?
| | Transgenes | 3 | 2026 | 190 | 0.250 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 956 | 0.250 |
Why?
| | Lung Neoplasms | 2 | 2018 | 2667 | 0.240 |
Why?
| | Recombination, Genetic | 5 | 2015 | 205 | 0.240 |
Why?
| | Pedigree | 5 | 2017 | 515 | 0.240 |
Why?
| | Janus Kinases | 1 | 2026 | 21 | 0.240 |
Why?
| | STAT Transcription Factors | 1 | 2026 | 25 | 0.240 |
Why?
| | Nanodiamonds | 1 | 2026 | 1 | 0.240 |
Why?
| | Radiography, Interventional | 1 | 2007 | 128 | 0.240 |
Why?
| | Inflammation | 4 | 2025 | 2883 | 0.240 |
Why?
| | Nuclear Pore | 1 | 2026 | 19 | 0.240 |
Why?
| | Homozygote | 3 | 2017 | 199 | 0.230 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2017 | 979 | 0.230 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2026 | 56 | 0.230 |
Why?
| | Sex-Determining Region Y Protein | 5 | 2016 | 7 | 0.230 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2009 | 339 | 0.230 |
Why?
| | Receptor, Adenosine A2A | 1 | 2025 | 23 | 0.230 |
Why?
| | DNA Primers | 9 | 2011 | 505 | 0.230 |
Why?
| | Interleukin-12 | 1 | 2026 | 115 | 0.230 |
Why?
| | Combinatorial Chemistry Techniques | 1 | 2025 | 17 | 0.230 |
Why?
| | Nuclear Envelope | 1 | 2026 | 45 | 0.230 |
Why?
| | Receptors, Notch | 1 | 2026 | 90 | 0.220 |
Why?
| | Immune Tolerance | 2 | 2025 | 385 | 0.220 |
Why?
| | Interferon Type I | 1 | 2026 | 147 | 0.220 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.220 |
Why?
| | Blood Coagulation | 1 | 2007 | 274 | 0.220 |
Why?
| | Heart Arrest | 1 | 2009 | 411 | 0.220 |
Why?
| | Transglutaminases | 1 | 2026 | 159 | 0.220 |
Why?
| | Antigen Presentation | 1 | 2026 | 208 | 0.220 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2025 | 35 | 0.220 |
Why?
| | Macrophages | 4 | 2025 | 1507 | 0.220 |
Why?
| | Lubricants | 1 | 2024 | 3 | 0.220 |
Why?
| | Biofouling | 1 | 2024 | 8 | 0.220 |
Why?
| | Silver Compounds | 1 | 2024 | 5 | 0.220 |
Why?
| | Adsorption | 2 | 2026 | 153 | 0.220 |
Why?
| | Biological Evolution | 4 | 2010 | 468 | 0.220 |
Why?
| | Interleukin-4 | 1 | 2025 | 207 | 0.220 |
Why?
| | Leukocytes, Mononuclear | 3 | 2023 | 574 | 0.220 |
Why?
| | MCF-7 Cells | 2 | 2015 | 133 | 0.220 |
Why?
| | rab27 GTP-Binding Proteins | 1 | 2024 | 1 | 0.220 |
Why?
| | Durapatite | 1 | 2024 | 37 | 0.210 |
Why?
| | Sarcoma, Ewing | 1 | 2025 | 103 | 0.210 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 74 | 0.210 |
Why?
| | Elasticity | 1 | 2025 | 189 | 0.210 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2025 | 129 | 0.210 |
Why?
| | DNA, B-Form | 1 | 2024 | 2 | 0.210 |
Why?
| | Gonadoblastoma | 1 | 2004 | 7 | 0.210 |
Why?
| | Cholic Acids | 1 | 2024 | 13 | 0.210 |
Why?
| | Antibodies, Viral | 2 | 2025 | 674 | 0.210 |
Why?
| | Eukaryotic Initiation Factor-2 | 4 | 2016 | 32 | 0.200 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2012 | 328 | 0.200 |
Why?
| | Injections, Intravenous | 1 | 2024 | 197 | 0.200 |
Why?
| | Cellular Microenvironment | 1 | 2024 | 93 | 0.200 |
Why?
| | Lipid Bilayers | 2 | 2022 | 103 | 0.200 |
Why?
| | Vaccines, DNA | 1 | 2024 | 32 | 0.200 |
Why?
| | Semen | 1 | 2023 | 24 | 0.200 |
Why?
| | Myocardial Contraction | 1 | 2025 | 293 | 0.200 |
Why?
| | Injections, Intramuscular | 1 | 2024 | 146 | 0.200 |
Why?
| | Genome | 3 | 2002 | 305 | 0.200 |
Why?
| | Proteolysis | 1 | 2024 | 172 | 0.200 |
Why?
| | Plant Immunity | 1 | 2023 | 4 | 0.200 |
Why?
| | Macrophage-1 Antigen | 2 | 2014 | 26 | 0.200 |
Why?
| | Cyclophilin A | 1 | 2023 | 27 | 0.190 |
Why?
| | Cell Separation | 2 | 2015 | 306 | 0.190 |
Why?
| | Peritoneal Fibrosis | 1 | 2023 | 2 | 0.190 |
Why?
| | ras Proteins | 1 | 2024 | 150 | 0.190 |
Why?
| | Macrophage Activation | 1 | 2024 | 181 | 0.190 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 254 | 0.190 |
Why?
| | Promoter Regions, Genetic | 1 | 2007 | 1247 | 0.190 |
Why?
| | Biomarkers, Tumor | 2 | 2015 | 1329 | 0.190 |
Why?
| | Neoplasm Proteins | 2 | 2017 | 442 | 0.190 |
Why?
| | Pesticides | 1 | 2023 | 59 | 0.190 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2023 | 103 | 0.190 |
Why?
| | Cell Nucleus | 1 | 2026 | 588 | 0.190 |
Why?
| | Immune System | 1 | 2024 | 180 | 0.180 |
Why?
| | Influenza, Human | 2 | 2024 | 624 | 0.180 |
Why?
| | Hydroxycholesterols | 1 | 2022 | 5 | 0.180 |
Why?
| | Forkhead Transcription Factors | 1 | 2023 | 209 | 0.180 |
Why?
| | Chromosome Pairing | 3 | 2011 | 11 | 0.180 |
Why?
| | Sequence Homology, Nucleic Acid | 3 | 2012 | 157 | 0.180 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 611 | 0.180 |
Why?
| | Emergency Medical Services | 1 | 2009 | 684 | 0.180 |
Why?
| | Zika Virus | 1 | 2023 | 136 | 0.180 |
Why?
| | Heterozygote | 4 | 2017 | 314 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2026 | 293 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2026 | 534 | 0.180 |
Why?
| | Reproductive Health | 1 | 2023 | 91 | 0.180 |
Why?
| | H-Y Antigen | 4 | 2000 | 10 | 0.180 |
Why?
| | Brain Diseases | 1 | 2023 | 155 | 0.180 |
Why?
| | Pneumonia, Viral | 2 | 2024 | 391 | 0.180 |
Why?
| | HeLa Cells | 3 | 2018 | 632 | 0.180 |
Why?
| | Phenotype | 7 | 2025 | 3170 | 0.180 |
Why?
| | Lymphocyte Activation | 1 | 2026 | 1133 | 0.170 |
Why?
| | Ions | 1 | 2021 | 66 | 0.170 |
Why?
| | Surface Properties | 2 | 2024 | 386 | 0.170 |
Why?
| | Calcium-Binding Proteins | 2 | 2024 | 221 | 0.170 |
Why?
| | Thrombosis | 2 | 2023 | 400 | 0.170 |
Why?
| | Antibodies | 1 | 2023 | 397 | 0.170 |
Why?
| | Zika Virus Infection | 1 | 2023 | 172 | 0.170 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2017 | 910 | 0.170 |
Why?
| | Contrast Media | 1 | 2024 | 497 | 0.170 |
Why?
| | Interleukin-2 | 1 | 2022 | 440 | 0.170 |
Why?
| | Myocytes, Cardiac | 2 | 2025 | 546 | 0.170 |
Why?
| | Immunization | 1 | 2023 | 375 | 0.170 |
Why?
| | Particle Size | 2 | 2024 | 381 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 266 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2026 | 641 | 0.170 |
Why?
| | DNA Mutational Analysis | 5 | 2010 | 410 | 0.170 |
Why?
| | Amino Acid Sequence | 10 | 2011 | 2131 | 0.170 |
Why?
| | Nanospheres | 1 | 2020 | 3 | 0.160 |
Why?
| | Gene Silencing | 2 | 2020 | 202 | 0.160 |
Why?
| | Teratozoospermia | 2 | 2017 | 3 | 0.160 |
Why?
| | Women's Health | 1 | 2023 | 316 | 0.160 |
Why?
| | Alleles | 3 | 2017 | 896 | 0.160 |
Why?
| | Cell Cycle | 1 | 2004 | 598 | 0.160 |
Why?
| | Legislation, Drug | 1 | 2021 | 73 | 0.160 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 287 | 0.160 |
Why?
| | Sex Chromosome Aberrations | 4 | 2007 | 69 | 0.160 |
Why?
| | United States | 8 | 2024 | 16123 | 0.160 |
Why?
| | Glioblastoma | 1 | 2024 | 354 | 0.160 |
Why?
| | Stem Cell Niche | 1 | 2020 | 57 | 0.160 |
Why?
| | Myocardium | 1 | 2025 | 935 | 0.150 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 396 | 0.150 |
Why?
| | Polymerase Chain Reaction | 7 | 2011 | 1043 | 0.150 |
Why?
| | Delayed-Action Preparations | 1 | 2020 | 189 | 0.150 |
Why?
| | Activated Protein C Resistance | 1 | 2019 | 3 | 0.150 |
Why?
| | Reproductive Techniques, Assisted | 2 | 2016 | 47 | 0.150 |
Why?
| | Physician Assistants | 1 | 2021 | 101 | 0.150 |
Why?
| | Bacterial Toxins | 2 | 2012 | 108 | 0.150 |
Why?
| | Coculture Techniques | 1 | 2020 | 247 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 883 | 0.140 |
Why?
| | Swine | 1 | 2021 | 826 | 0.140 |
Why?
| | Nurse Practitioners | 1 | 2021 | 141 | 0.140 |
Why?
| | Narcotic Antagonists | 1 | 2021 | 203 | 0.140 |
Why?
| | Blotting, Southern | 6 | 2000 | 85 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2021 | 288 | 0.140 |
Why?
| | Sheep | 1 | 2021 | 876 | 0.140 |
Why?
| | Genotype | 5 | 2010 | 1857 | 0.140 |
Why?
| | Antigens | 1 | 2020 | 348 | 0.140 |
Why?
| | Axoneme | 1 | 2018 | 10 | 0.140 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 838 | 0.140 |
Why?
| | Cell Line | 6 | 2020 | 2823 | 0.140 |
Why?
| | Genetics, Population | 2 | 2010 | 217 | 0.140 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2023 | 499 | 0.140 |
Why?
| | Signal Transduction | 4 | 2026 | 5223 | 0.140 |
Why?
| | Dyneins | 1 | 2018 | 34 | 0.140 |
Why?
| | Viruses | 1 | 2020 | 166 | 0.140 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 230 | 0.140 |
Why?
| | Cytokines | 2 | 2024 | 2069 | 0.140 |
Why?
| | Anti-Inflammatory Agents | 1 | 2022 | 478 | 0.140 |
Why?
| | Disease Models, Animal | 3 | 2024 | 4568 | 0.140 |
Why?
| | Tetrahymena | 1 | 2018 | 158 | 0.130 |
Why?
| | Recombinant Proteins | 3 | 2024 | 1368 | 0.130 |
Why?
| | Zinc Oxide | 1 | 2017 | 9 | 0.130 |
Why?
| | Health Policy | 1 | 2021 | 400 | 0.130 |
Why?
| | Fetus | 1 | 2022 | 804 | 0.130 |
Why?
| | Serine Peptidase Inhibitors, Kazal Type | 1 | 2017 | 1 | 0.130 |
Why?
| | Asthenozoospermia | 1 | 2017 | 2 | 0.130 |
Why?
| | INDEL Mutation | 1 | 2017 | 22 | 0.130 |
Why?
| | Nanofibers | 1 | 2017 | 23 | 0.130 |
Why?
| | Pachytene Stage | 2 | 2008 | 2 | 0.130 |
Why?
| | Gene Frequency | 2 | 2017 | 489 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2026 | 928 | 0.130 |
Why?
| | Buprenorphine | 1 | 2021 | 192 | 0.130 |
Why?
| | Chromatin | 2 | 2017 | 553 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2016 | 224 | 0.130 |
Why?
| | HT29 Cells | 1 | 2017 | 37 | 0.130 |
Why?
| | Exome | 1 | 2018 | 229 | 0.130 |
Why?
| | Biological Transport | 2 | 2020 | 424 | 0.130 |
Why?
| | Aurora Kinase C | 1 | 2016 | 2 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1270 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 1 | 2007 | 2770 | 0.130 |
Why?
| | Cilia | 1 | 2018 | 172 | 0.120 |
Why?
| | Melanoma | 1 | 2023 | 761 | 0.120 |
Why?
| | Isochromosomes | 1 | 1996 | 2 | 0.120 |
Why?
| | Binding Sites | 2 | 2012 | 1311 | 0.120 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 414 | 0.120 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2601 | 0.120 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 196 | 0.120 |
Why?
| | Factor VII Deficiency | 2 | 2007 | 5 | 0.120 |
Why?
| | Seminiferous Tubules | 1 | 2016 | 13 | 0.120 |
Why?
| | Genetic Counseling | 1 | 2016 | 80 | 0.120 |
Why?
| | Physical Chromosome Mapping | 1 | 2016 | 21 | 0.120 |
Why?
| | Drug Synergism | 1 | 2017 | 354 | 0.120 |
Why?
| | Biomedical Research | 1 | 2023 | 719 | 0.120 |
Why?
| | Melanoma, Experimental | 1 | 2016 | 109 | 0.120 |
Why?
| | Mothers | 1 | 2022 | 765 | 0.120 |
Why?
| | Pseudoautosomal Regions | 1 | 2015 | 1 | 0.120 |
Why?
| | Zinc Fingers | 2 | 2012 | 50 | 0.120 |
Why?
| | SOX9 Transcription Factor | 1 | 2016 | 27 | 0.120 |
Why?
| | Bernard-Soulier Syndrome | 1 | 2015 | 1 | 0.110 |
Why?
| | Ubiquitin-Protein Ligases | 4 | 2000 | 194 | 0.110 |
Why?
| | Adult | 13 | 2017 | 40872 | 0.110 |
Why?
| | Sex Chromosomes | 4 | 2011 | 58 | 0.110 |
Why?
| | Phylogeny | 3 | 2001 | 917 | 0.110 |
Why?
| | Neurons | 1 | 2024 | 1652 | 0.110 |
Why?
| | Epithelial Cell Adhesion Molecule | 1 | 2015 | 10 | 0.110 |
Why?
| | Glycoproteins | 1 | 2017 | 354 | 0.110 |
Why?
| | Hydrogen-Ion Concentration | 3 | 2026 | 532 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 923 | 0.110 |
Why?
| | Blood Cells | 1 | 2015 | 38 | 0.110 |
Why?
| | Cell Survival | 2 | 2019 | 1103 | 0.110 |
Why?
| | Tissue Scaffolds | 1 | 2017 | 221 | 0.110 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2015 | 50 | 0.110 |
Why?
| | Deleted in Azoospermia 1 Protein | 3 | 2005 | 4 | 0.110 |
Why?
| | Lamin Type B | 1 | 2014 | 6 | 0.110 |
Why?
| | Morphogenesis | 1 | 2016 | 171 | 0.110 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2015 | 56 | 0.110 |
Why?
| | Gene Dosage | 4 | 2016 | 145 | 0.110 |
Why?
| | Conserved Sequence | 2 | 2012 | 244 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2020 | 603 | 0.110 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 334 | 0.110 |
Why?
| | Interphase | 1 | 2014 | 38 | 0.110 |
Why?
| | Rheology | 1 | 2015 | 94 | 0.110 |
Why?
| | Sequence Tagged Sites | 2 | 2011 | 7 | 0.110 |
Why?
| | Receptors, Death Domain | 1 | 2014 | 4 | 0.110 |
Why?
| | Cells, Cultured | 3 | 2020 | 4151 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2024 | 1331 | 0.100 |
Why?
| | ADAM17 Protein | 1 | 2014 | 42 | 0.100 |
Why?
| | Hemorheology | 1 | 2014 | 24 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2017 | 457 | 0.100 |
Why?
| | Nanotubes, Carbon | 1 | 2014 | 46 | 0.100 |
Why?
| | Taste | 1 | 2016 | 238 | 0.100 |
Why?
| | ADAM Proteins | 1 | 2014 | 64 | 0.100 |
Why?
| | Models, Animal | 1 | 2016 | 392 | 0.100 |
Why?
| | Partial Thromboplastin Time | 2 | 2019 | 53 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 440 | 0.100 |
Why?
| | Metals | 1 | 2014 | 136 | 0.100 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 264 | 0.100 |
Why?
| | Serum Albumin | 1 | 2014 | 147 | 0.100 |
Why?
| | Ubiquitin-Activating Enzymes | 3 | 2000 | 20 | 0.090 |
Why?
| | Laboratories | 2 | 2010 | 110 | 0.090 |
Why?
| | Marsupialia | 1 | 1992 | 8 | 0.090 |
Why?
| | Bacterial Proteins | 2 | 2012 | 968 | 0.090 |
Why?
| | Cytosol | 2 | 2024 | 213 | 0.090 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 2012 | 38 | 0.090 |
Why?
| | Biomechanical Phenomena | 2 | 2015 | 860 | 0.090 |
Why?
| | DNA Fragmentation | 1 | 2012 | 40 | 0.090 |
Why?
| | Physicians | 1 | 2021 | 956 | 0.090 |
Why?
| | Chromosome Breakpoints | 1 | 2011 | 9 | 0.090 |
Why?
| | Time Factors | 2 | 2014 | 7133 | 0.090 |
Why?
| | Sperm Count | 1 | 2011 | 22 | 0.090 |
Why?
| | Founder Effect | 1 | 2011 | 13 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2005 | 615 | 0.090 |
Why?
| | Heat Shock Transcription Factors | 1 | 2011 | 21 | 0.090 |
Why?
| | France | 1 | 2011 | 40 | 0.090 |
Why?
| | Microbiological Techniques | 1 | 2012 | 30 | 0.090 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2012 | 29 | 0.090 |
Why?
| | Germ Cells | 1 | 2012 | 66 | 0.090 |
Why?
| | Plasmids | 2 | 2023 | 373 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 966 | 0.090 |
Why?
| | Protease Inhibitors | 1 | 2012 | 102 | 0.090 |
Why?
| | Disorders of Sex Development | 1 | 1992 | 40 | 0.090 |
Why?
| | Rats | 5 | 2025 | 5585 | 0.080 |
Why?
| | Metaphase | 1 | 2011 | 33 | 0.080 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2012 | 104 | 0.080 |
Why?
| | Interleukin-8 | 1 | 2012 | 269 | 0.080 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 96 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2024 | 2393 | 0.080 |
Why?
| | Disease Notification | 1 | 2010 | 16 | 0.080 |
Why?
| | Comoros | 1 | 2010 | 1 | 0.080 |
Why?
| | Indian Ocean | 1 | 2010 | 1 | 0.080 |
Why?
| | Cultural Evolution | 1 | 2010 | 5 | 0.080 |
Why?
| | Africa, Eastern | 1 | 2010 | 12 | 0.080 |
Why?
| | Bioterrorism | 1 | 2010 | 31 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2022 | 6464 | 0.080 |
Why?
| | Protein Transport | 1 | 2012 | 442 | 0.080 |
Why?
| | Extracellular Matrix | 1 | 2015 | 562 | 0.080 |
Why?
| | Genetic Markers | 4 | 2001 | 338 | 0.080 |
Why?
| | Haplotypes | 2 | 2009 | 500 | 0.080 |
Why?
| | Enzyme Activation | 3 | 2019 | 762 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2011 | 371 | 0.080 |
Why?
| | Arabs | 1 | 2009 | 10 | 0.080 |
Why?
| | Gene Flow | 1 | 2010 | 87 | 0.080 |
Why?
| | Alternative Splicing | 1 | 2012 | 248 | 0.080 |
Why?
| | Mice, Inbred Strains | 3 | 2000 | 396 | 0.070 |
Why?
| | Viral Load | 1 | 2011 | 526 | 0.070 |
Why?
| | Cohort Studies | 2 | 2010 | 6032 | 0.070 |
Why?
| | Washington | 1 | 2009 | 149 | 0.070 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 159 | 0.070 |
Why?
| | SUMO-1 Protein | 1 | 2008 | 18 | 0.070 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 981 | 0.070 |
Why?
| | Mice, Transgenic | 5 | 2016 | 2191 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2025 | 936 | 0.070 |
Why?
| | Sequence Alignment | 2 | 2011 | 362 | 0.070 |
Why?
| | Erythrocytes | 1 | 2014 | 749 | 0.070 |
Why?
| | Introns | 2 | 2000 | 256 | 0.070 |
Why?
| | Heterochromatin | 1 | 2008 | 66 | 0.070 |
Why?
| | Sequence Analysis, DNA | 1 | 2010 | 778 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2028 | 0.070 |
Why?
| | Factor IXa | 1 | 2007 | 16 | 0.070 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2007 | 88 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1372 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 2010 | 419 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2007 | 2399 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2004 | 630 | 0.060 |
Why?
| | Molecular Weight | 1 | 2007 | 312 | 0.060 |
Why?
| | Dimerization | 1 | 2007 | 189 | 0.060 |
Why?
| | Cricetinae | 1 | 2007 | 305 | 0.060 |
Why?
| | Thromboplastin | 1 | 2007 | 67 | 0.060 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2007 | 76 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 4 | 2001 | 387 | 0.060 |
Why?
| | Aged | 4 | 2017 | 26215 | 0.060 |
Why?
| | Actin Cytoskeleton | 1 | 1987 | 103 | 0.060 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2007 | 376 | 0.060 |
Why?
| | Up-Regulation | 2 | 2023 | 848 | 0.060 |
Why?
| | Language | 1 | 2009 | 324 | 0.060 |
Why?
| | Seminal Plasma Proteins | 1 | 2006 | 11 | 0.060 |
Why?
| | Prognosis | 1 | 2015 | 4329 | 0.060 |
Why?
| | Pharmacokinetics | 1 | 2026 | 33 | 0.060 |
Why?
| | Cytoskeleton | 1 | 1987 | 192 | 0.060 |
Why?
| | Automation | 1 | 2025 | 104 | 0.060 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2025 | 32 | 0.060 |
Why?
| | Transition Temperature | 1 | 2025 | 28 | 0.060 |
Why?
| | Evolution, Molecular | 2 | 2000 | 494 | 0.060 |
Why?
| | Factor VII | 1 | 2005 | 24 | 0.060 |
Why?
| | Apolipoproteins E | 1 | 2025 | 93 | 0.050 |
Why?
| | Gene Conversion | 1 | 2004 | 7 | 0.050 |
Why?
| | Phosphatidylethanolamines | 1 | 2025 | 77 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2013 | 962 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 751 | 0.050 |
Why?
| | Actins | 1 | 1987 | 426 | 0.050 |
Why?
| | Chromosome Inversion | 1 | 2004 | 20 | 0.050 |
Why?
| | Blotting, Western | 1 | 2007 | 1184 | 0.050 |
Why?
| | Leukocyte Common Antigens | 1 | 2024 | 87 | 0.050 |
Why?
| | Molecular Dynamics Simulation | 1 | 2026 | 265 | 0.050 |
Why?
| | Cell Lineage | 1 | 2026 | 378 | 0.050 |
Why?
| | Biomarkers | 1 | 2015 | 4302 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2933 | 0.050 |
Why?
| | Chemokine CXCL12 | 1 | 2023 | 86 | 0.050 |
Why?
| | Germ-Line Mutation | 1 | 2004 | 177 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1711 | 0.050 |
Why?
| | Disease Resistance | 1 | 2023 | 29 | 0.050 |
Why?
| | Crops, Agricultural | 1 | 2023 | 30 | 0.050 |
Why?
| | Fluorocarbons | 1 | 2024 | 120 | 0.050 |
Why?
| | Plant Diseases | 1 | 2023 | 44 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2023 | 132 | 0.050 |
Why?
| | Biological Factors | 1 | 2023 | 39 | 0.050 |
Why?
| | Immunity | 1 | 2023 | 140 | 0.050 |
Why?
| | Genetic Research | 1 | 2023 | 17 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2024 | 156 | 0.050 |
Why?
| | RNA Interference | 1 | 2024 | 475 | 0.050 |
Why?
| | Foreign-Body Reaction | 1 | 2023 | 34 | 0.050 |
Why?
| | Sex Determination Analysis | 2 | 1992 | 10 | 0.050 |
Why?
| | Bacterial Infections | 2 | 2017 | 246 | 0.050 |
Why?
| | DNA, Complementary | 2 | 2000 | 273 | 0.050 |
Why?
| | Retroelements | 2 | 2001 | 50 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 1 | 2024 | 276 | 0.040 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2002 | 15 | 0.040 |
Why?
| | Minor Histocompatibility Antigens | 2 | 2000 | 47 | 0.040 |
Why?
| | Genetic Testing | 2 | 2005 | 483 | 0.040 |
Why?
| | Chromosomes, Human | 2 | 1998 | 44 | 0.040 |
Why?
| | In Situ Nick-End Labeling | 2 | 2012 | 120 | 0.040 |
Why?
| | Young Adult | 3 | 2017 | 14251 | 0.040 |
Why?
| | DEAD-box RNA Helicases | 2 | 2000 | 84 | 0.040 |
Why?
| | Drug Liberation | 1 | 2021 | 36 | 0.040 |
Why?
| | Nanotechnology | 1 | 2022 | 114 | 0.040 |
Why?
| | Child | 5 | 2016 | 22739 | 0.040 |
Why?
| | Middle Aged | 4 | 2017 | 36302 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 89 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 244 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2024 | 474 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2024 | 340 | 0.040 |
Why?
| | Sequence Homology | 1 | 2000 | 43 | 0.040 |
Why?
| | Cloning, Molecular | 3 | 1998 | 538 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 2181 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2008 | 3634 | 0.040 |
Why?
| | Genes, MHC Class II | 1 | 2000 | 77 | 0.040 |
Why?
| | Protons | 1 | 2020 | 96 | 0.040 |
Why?
| | NF-kappa B | 1 | 2024 | 667 | 0.040 |
Why?
| | Wound Healing | 1 | 2023 | 355 | 0.040 |
Why?
| | Quartz Crystal Microbalance Techniques | 1 | 2019 | 7 | 0.040 |
Why?
| | Protein Conformation | 1 | 2023 | 938 | 0.040 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 2019 | 6 | 0.040 |
Why?
| | Histocompatibility Antigens | 1 | 2000 | 102 | 0.040 |
Why?
| | Factor X | 1 | 2019 | 26 | 0.040 |
Why?
| | Mammals | 2 | 1998 | 286 | 0.040 |
Why?
| | Stereoisomerism | 1 | 2019 | 103 | 0.040 |
Why?
| | Prothrombin Time | 1 | 2019 | 33 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 155 | 0.040 |
Why?
| | Blood Platelets | 1 | 2023 | 379 | 0.040 |
Why?
| | Proteomics | 1 | 2026 | 1188 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2020 | 322 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2000 | 166 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2000 | 174 | 0.040 |
Why?
| | Quality Control | 1 | 2019 | 161 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2024 | 1217 | 0.040 |
Why?
| | Heart | 1 | 2023 | 626 | 0.040 |
Why?
| | Chromosomes, Bacterial | 1 | 1998 | 12 | 0.040 |
Why?
| | Dosage Compensation, Genetic | 1 | 1998 | 12 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 741 | 0.040 |
Why?
| | Microscopy, Confocal | 1 | 2019 | 319 | 0.030 |
Why?
| | Platypus | 1 | 1998 | 1 | 0.030 |
Why?
| | Thrombin | 1 | 2019 | 172 | 0.030 |
Why?
| | Cysteine | 1 | 2019 | 211 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2021 | 858 | 0.030 |
Why?
| | Sex Determination Processes | 1 | 1998 | 11 | 0.030 |
Why?
| | Gene Expression | 2 | 1994 | 1478 | 0.030 |
Why?
| | Biosensing Techniques | 1 | 2019 | 142 | 0.030 |
Why?
| | Specimen Handling | 1 | 2019 | 183 | 0.030 |
Why?
| | Thermodynamics | 1 | 2019 | 419 | 0.030 |
Why?
| | Hemorrhage | 1 | 2023 | 822 | 0.030 |
Why?
| | Tensile Strength | 1 | 2017 | 98 | 0.030 |
Why?
| | Primates | 1 | 1998 | 133 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2016 | 15 | 0.030 |
Why?
| | Bacterial Adhesion | 1 | 2017 | 109 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2009 | 8346 | 0.030 |
Why?
| | Species Specificity | 1 | 1998 | 546 | 0.030 |
Why?
| | Muridae | 1 | 1996 | 6 | 0.030 |
Why?
| | Genetic Loci | 2 | 2009 | 267 | 0.030 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2017 | 108 | 0.030 |
Why?
| | Drosophila | 1 | 1998 | 166 | 0.030 |
Why?
| | Ovalbumin | 1 | 2016 | 194 | 0.030 |
Why?
| | Vaccines, Synthetic | 1 | 2016 | 137 | 0.030 |
Why?
| | Spermatogonia | 1 | 2016 | 16 | 0.030 |
Why?
| | Haploidy | 1 | 2016 | 28 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 6 | 0.030 |
Why?
| | Materials Testing | 1 | 2017 | 345 | 0.030 |
Why?
| | Restriction Mapping | 2 | 1994 | 81 | 0.030 |
Why?
| | Cosmids | 1 | 1995 | 8 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1062 | 0.030 |
Why?
| | Oocytes | 1 | 2016 | 185 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 1994 | 318 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2017 | 209 | 0.030 |
Why?
| | Acrosome | 1 | 2014 | 6 | 0.030 |
Why?
| | Patient Selection | 1 | 2019 | 739 | 0.030 |
Why?
| | Cell Shape | 1 | 2015 | 56 | 0.030 |
Why?
| | Family Health | 2 | 2007 | 191 | 0.030 |
Why?
| | Genes, Y-Linked | 1 | 2014 | 1 | 0.030 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2015 | 76 | 0.030 |
Why?
| | Fluorescence | 1 | 2015 | 159 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1751 | 0.030 |
Why?
| | Mice, Inbred CBA | 3 | 2000 | 57 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 174 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2015 | 203 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 867 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1994 | 177 | 0.030 |
Why?
| | Anticoagulants | 1 | 2019 | 748 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3416 | 0.020 |
Why?
| | Hominidae | 1 | 1994 | 87 | 0.020 |
Why?
| | Adolescent | 3 | 2010 | 22573 | 0.020 |
Why?
| | Epitopes | 1 | 1995 | 473 | 0.020 |
Why?
| | Cadherins | 1 | 2015 | 200 | 0.020 |
Why?
| | Emergency Medicine | 1 | 2016 | 282 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 124 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2014 | 399 | 0.020 |
Why?
| | Karyotyping | 2 | 2012 | 106 | 0.020 |
Why?
| | Tissue Engineering | 1 | 2017 | 438 | 0.020 |
Why?
| | Research Design | 1 | 2019 | 1139 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2009 | 17325 | 0.020 |
Why?
| | Family Practice | 1 | 2016 | 407 | 0.020 |
Why?
| | Sex Characteristics | 2 | 1995 | 789 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1211 | 0.020 |
Why?
| | Cattle | 1 | 2015 | 946 | 0.020 |
Why?
| | Amsacrine | 1 | 1992 | 1 | 0.020 |
Why?
| | Chromosome Walking | 1 | 1992 | 1 | 0.020 |
Why?
| | DNA, Superhelical | 1 | 1992 | 12 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1991 | 60 | 0.020 |
Why?
| | Dinucleoside Phosphates | 1 | 1992 | 31 | 0.020 |
Why?
| | BK Virus | 1 | 2011 | 18 | 0.020 |
Why?
| | DNA Topoisomerases, Type II | 1 | 1992 | 42 | 0.020 |
Why?
| | Graft Rejection | 1 | 1995 | 521 | 0.020 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2002 | 26 | 0.020 |
Why?
| | Bacteria | 1 | 2017 | 766 | 0.020 |
Why?
| | Equipment Design | 1 | 2013 | 525 | 0.020 |
Why?
| | Antigens, CD | 1 | 2015 | 558 | 0.020 |
Why?
| | Gene Library | 1 | 1992 | 122 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 1992 | 160 | 0.020 |
Why?
| | Histological Techniques | 1 | 2011 | 39 | 0.020 |
Why?
| | Caspases | 1 | 2012 | 233 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 337 | 0.020 |
Why?
| | Brucella abortus | 1 | 2010 | 4 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 208 | 0.020 |
Why?
| | Bacillus anthracis | 1 | 2010 | 13 | 0.020 |
Why?
| | Observer Variation | 1 | 2011 | 357 | 0.020 |
Why?
| | Herpesvirus 4, Human | 1 | 2011 | 172 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2011 | 168 | 0.020 |
Why?
| | Civil Defense | 1 | 2010 | 20 | 0.020 |
Why?
| | Pathology, Clinical | 1 | 2010 | 29 | 0.020 |
Why?
| | Pathology | 1 | 2010 | 21 | 0.020 |
Why?
| | Sentinel Surveillance | 1 | 2010 | 46 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 408 | 0.020 |
Why?
| | Models, Chemical | 1 | 1992 | 250 | 0.020 |
Why?
| | Health Planning | 1 | 2010 | 47 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 365 | 0.020 |
Why?
| | Francisella tularensis | 1 | 2010 | 33 | 0.020 |
Why?
| | Resource Allocation | 1 | 2010 | 52 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2015 | 892 | 0.020 |
Why?
| | Leukemia | 1 | 1992 | 246 | 0.020 |
Why?
| | Ovary | 1 | 2011 | 234 | 0.020 |
Why?
| | Geography | 1 | 2009 | 187 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2010 | 536 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 157 | 0.020 |
Why?
| | Feces | 1 | 2012 | 496 | 0.020 |
Why?
| | Histone Demethylases | 2 | 2000 | 38 | 0.020 |
Why?
| | Pediatrics | 1 | 2016 | 1125 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1547 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2008 | 130 | 0.020 |
Why?
| | Cell-Free System | 1 | 1987 | 53 | 0.020 |
Why?
| | Neurotoxins | 1 | 1987 | 28 | 0.020 |
Why?
| | Monoamine Oxidase | 1 | 1987 | 27 | 0.020 |
Why?
| | Viscosity | 1 | 1987 | 92 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 2000 | 0.020 |
Why?
| | Indicators and Reagents | 1 | 2007 | 106 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2014 | 2050 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2007 | 187 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1925 | 0.020 |
Why?
| | X Chromosome Inactivation | 1 | 2006 | 25 | 0.010 |
Why?
| | XYY Karyotype | 1 | 2006 | 24 | 0.010 |
Why?
| | Public Health | 1 | 2010 | 574 | 0.010 |
Why?
| | Mice, Inbred C3H | 2 | 1996 | 254 | 0.010 |
Why?
| | Frameshift Mutation | 1 | 2004 | 31 | 0.010 |
Why?
| | Inheritance Patterns | 1 | 2004 | 45 | 0.010 |
Why?
| | Prospective Studies | 1 | 2016 | 8075 | 0.010 |
Why?
| | Mosaicism | 1 | 2004 | 73 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 6085 | 0.010 |
Why?
| | Disease Management | 1 | 2007 | 653 | 0.010 |
Why?
| | Lymphocytes | 1 | 2004 | 376 | 0.010 |
Why?
| | Mutagenesis, Insertional | 1 | 2002 | 68 | 0.010 |
Why?
| | RNA Splice Sites | 1 | 2002 | 51 | 0.010 |
Why?
| | Codon, Nonsense | 1 | 2002 | 45 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1723 | 0.010 |
Why?
| | Fibroblasts | 1 | 1987 | 1027 | 0.010 |
Why?
| | Hybrid Cells | 1 | 2001 | 49 | 0.010 |
Why?
| | Blood Specimen Collection | 1 | 2001 | 37 | 0.010 |
Why?
| | Dogs | 1 | 2002 | 478 | 0.010 |
Why?
| | H-2 Antigens | 1 | 2000 | 111 | 0.010 |
Why?
| | RNA Splicing | 1 | 2001 | 284 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2001 | 334 | 0.010 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 1998 | 22 | 0.010 |
Why?
| | Isoantibodies | 1 | 1999 | 57 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1998 | 203 | 0.010 |
Why?
| | Child, Preschool | 3 | 2005 | 11868 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 2001 | 644 | 0.010 |
Why?
| | Infant | 2 | 2004 | 10090 | 0.010 |
Why?
| | Oxidoreductases, N-Demethylating | 1 | 1996 | 17 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1996 | 123 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1998 | 1261 | 0.010 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1994 | 5 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1994 | 35 | 0.010 |
Why?
| | Crossing Over, Genetic | 1 | 1992 | 7 | 0.010 |
Why?
| | Aneuploidy | 1 | 1973 | 91 | 0.010 |
Why?
| | DNA Topoisomerases, Type I | 1 | 1992 | 14 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 1992 | 34 | 0.010 |
Why?
| | Deoxyribonucleotides | 1 | 1991 | 20 | 0.010 |
Why?
| | Carbamates | 1 | 1992 | 50 | 0.010 |
Why?
| | Vertebrates | 1 | 1991 | 63 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1992 | 887 | 0.000 |
Why?
| | Sulfonamides | 1 | 1992 | 583 | 0.000 |
Why?
| | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 1987 | 4 | 0.000 |
Why?
| | Pargyline | 1 | 1987 | 3 | 0.000 |
Why?
| | Computer Simulation | 1 | 1992 | 1003 | 0.000 |
Why?
| | Risk Factors | 1 | 2001 | 10917 | 0.000 |
Why?
| | Cerebrovascular Circulation | 1 | 1987 | 290 | 0.000 |
Why?
| | Kinetics | 1 | 1987 | 1568 | 0.000 |
Why?
| | Dermatoglyphics | 1 | 1973 | 2 | 0.000 |
Why?
| | Mouth Mucosa | 1 | 1973 | 85 | 0.000 |
Why?
| | Myopia | 1 | 1973 | 59 | 0.000 |
Why?
| | Intelligence | 1 | 1973 | 115 | 0.000 |
Why?
| | Personality Disorders | 1 | 1973 | 78 | 0.000 |
Why?
| | Syndrome | 1 | 1973 | 381 | 0.000 |
Why?
| | Body Height | 1 | 1973 | 203 | 0.000 |
Why?
|
|
Mitchell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|